ONYX

Onyx Biotec Share Price

 

 

Start SIP in ONYX

Start SIP

Performance

  • Low
  • ₹28
  • High
  • ₹35
  • 52 Week Low
  • ₹28
  • 52 Week High
  • ₹97
  • Open Price₹28
  • Previous Close₹31
  • Volume30,000

Investment Returns

  • Over 1 Month -17.23%
  • Over 3 Month -28.92%
  • Over 6 Month -39.03%
  • Over 1 Year -50.58%

Smart Investing Starts Here Start SIP with Onyx Biotec for Steady Growth!

Invest Now

Onyx Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 11.7
  • PEG Ratio
  • -
  • Market Cap Cr
  • 58
  • P/B Ratio
  • 1.1
  • Average True Range
  • 2.2
  • EPS
  • 2.33
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.97
  • RSI
  • 39.96
  • MFI
  • 39.35

Onyx Biotec Financials

Onyx Biotec Technicals

EMA & SMA

Current Price
₹31.95
+ 0.95 (3.06%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹34.24
  • 50 Day
  • ₹37.84
  • 100 Day
  • ₹42.21
  • 200 Day
  • ₹49.45

Resistance and Support

31.58 Pivot Speed
  • R3 41.67
  • R2 38.18
  • R1 35.07
  • S1 28.47
  • S2 24.98
  • S3 21.87

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Onyx Biotec Limited specializes in manufacturing biopharmaceutical products across two key segments: vaccines and therapeutic proteins. Operating in over 30 countries, it has three advanced production facilities catering to healthcare providers and pharmaceutical companies globally for critical disease treatments.

Onyx Biotec Ltd has an operating revenue of Rs. 150.29 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 10% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 12%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 17 which is a POOR score indicating inconsistency in earnings, a RS Rating of 4 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Onyx Biotec Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-05-28 Audited Results
2025-01-10 Quarterly Results

Onyx Biotec F&O

Onyx Biotec Shareholding Pattern

65.1%
0%
1.95%
0%
22.64%
10.31%

Onyx Biotec FAQs

Onyx Biotec share price is ₹31 As on 27 December, 2025 | 14:27

The Market Cap of Onyx Biotec is ₹57.9 Cr As on 27 December, 2025 | 14:27

The P/E ratio of Onyx Biotec is 11.7 As on 27 December, 2025 | 14:27

The PB ratio of Onyx Biotec is 1.1 As on 27 December, 2025 | 14:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23